Evidence map›Paper›PMID 39985668›Full record

Trial reportAging clinical and experimental research2025

Treatment of postmenopausal osteoporosis with recombinant human parathyroid hormone and electromagnetic field.

Miao Xuan, Bo Wang, Wanrong Bi, Ying Li, Lige Song, Zhuangli Xie, Qi Liu, Xiuzhen Zhang

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Aging clinical and experimental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Miao Xuan *Department of Endocrinology,School of Medicine，Tongji Hospital, Tongji University, Shanghai, 200065, China.
Bo Wang *Department of Endocrinology, School of Medicine, Yangpu Hospital, Tongji University, Shanghai, 200090, China.
Wanrong BiSchool of Medicine, Tongji University, Shanghai, 200331, China. biwanrong@tongji.edu.cn.
Ying LiDepartment of Endocrinology,School of Medicine，Tongji Hospital, Tongji University, Shanghai, 200065, China.
Lige SongDepartment of Endocrinology,School of Medicine，Tongji Hospital, Tongji University, Shanghai, 200065, China.
Zhuangli XieDepartment of Endocrinology,School of Medicine，Tongji Hospital, Tongji University, Shanghai, 200065, China.
Qi LiuDepartment of Endocrinology,School of Medicine，Tongji Hospital, Tongji University, Shanghai, 200065, China.
Xiuzhen ZhangDepartment of Endocrinology,School of Medicine，Tongji Hospital, Tongji University, Shanghai, 200065, China. xiuzhen@mail.tongji.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to investigate the effect of electromagnetic field (EMF) combined with recombinant human parathyroid hormone (rhPTH) on bone mineral density (BMD) and bone turnover indicators in postmenopausal osteoporosis (PMOP) patients.

methodsA total of 336 PMOP patients were randomly assigned into three groups: EMF + rhPTH group (n = 115), rhPTHx group (n = 113) and EMF group (n = 108). The lumbar spine and femoral neck BMDs were measured before treatment and at 6, 12, and 18 months after treatment. Blood calcium, bone alkaline phosphatase (BSAP), type I procollagen N-terminal peptide (PINP), and type I collagen C-terminal peptide/creatinine ratio (CTX/Cr) levels were measured before treatment and at 3, 6, 12, and 18 months after treatment.

resultsThe lumbar spine BMD was significantly increased at 6, 12, and 18 months after treatment, and the neck BMD was increased markedly at 18 months in both EMF + rhPTH group and rhPTH group as compared to those before treatment. There was significant difference in the lumbar spine BMD between EMF + rhPTH group and EMF group and between rhPTH group and EMF group at 6, 12, and 18 months after treatment. In the EMF + rhPTH group, at 3, 6, 12, and 18 months after treatment, blood calcium level was increased by 5.2%, 2.8%, 2.7%, and 3.1%, respectively; BASP level was increased by 80.9%, 120.3%, 84.1%, and 67.7%, respectively; PINP level was increased by 65.4%, 79.7%, 89.7%, and 74.5%, respectively; CTX/Cr was increased by 80.9%, 120.3%, 84.1%, and 67.7%, respectively; the bone metabolism indicators were markedly higher than those before treatment. In the rhPTH group, at 3, 6, 12, and 18 months after treatment, blood calcium level was increased by 5.1%, 3.3%, 3.0%, and 2.1%, respectively; BSAP level was increased by 51.6%, 81.4%, 101.1% and 56.3% respectively; PINP level was increased by 48.5%, 69.8%, 80.7% and 70.5% respectively; CTX/Cr was increased by 29.8%, 29.9%, 55.7%, and 44.8% respectively; the bone turnover indicators were significantly different from those before treatment (P < 0.01).

conclusionThe combination of EMF and rhPTH can significantly improve the bone turnover and BMD of PMOP patients, and may serve as a clinical treatment of PMOP.

Indexed as

Electromagnetic FieldsMagnetic Field TherapyOsteoporosis, PostmenopausalParathyroid HormoneAgedAlkaline PhosphataseBone DensityCalciumFemaleHumansLumbar VertebraeMiddle AgedRecombinant ProteinsAlkaline PhosphataseCalciumParathyroid HormoneRecombinant ProteinsBone densityElectromagnetic fieldPostmenopausal osteoporosisRecombinant human parathyroid hormone

Identifiers

PMID39985668
PMCPMC11846737

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.